[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567326":3},{"organization":4,"outcomesModule":7,"designInfo":39,"detailedDescription":38,"studyPopulation":42,"armGroups":38,"interventions":43,"overallOfficials":48,"centralContacts":52,"locations":61,"responsibleParty":80,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":38,"enrollmentInfo":97,"targetDuration":38,"studyType":100,"phases":38,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":64,"whyStopped":38,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"University of Oxford","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":38},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Fidelity","The proportion of prescriptions reviewed as intended (reviewed within 48hours with documentation of all 4 review components: indication, route, duration, stop date). Reported as a proportion of the number of possible reviews.","Evaluated over calendar month periods during months 4-6 (i.e. the three months immediately following implementation)",{"measure":14,"description":15,"timeFrame":12},"Reach","Proportion of eligible patients who receive a review",{"measure":17,"description":18,"timeFrame":19},"Adoption","Proportion of prescriptions reviewed as intended once implementation support has been withdrawn","Evaluated over the calendar month period of month 7",[21,25,29,32,35],{"measure":22,"description":23,"timeFrame":24},"Antimicrobial Density (AD)","Defined Daily Dose \u002F 1000 patient-days. This measure of antimicrobial consumption will compare prescribed daily doses of antimicrobials to those specified by the World Health Organization (WHO) (Anatomical Therapeutic Classification (ATC) J01 Defined Daily Doses). To correct for ICU unit size the investigators will standardise by number of admitted patient-days during that month in that ICU.","Evaluated over calendar month periods during months 1-7 of the study.",{"measure":26,"description":27,"timeFrame":28},"Duration of Therapy","Number of Days of antimicrobial Therapy \u002F 1000 patient-days Analysed at the ICU level","Evaluated over calendar month periods during months 1-7 of the study",{"measure":30,"description":31,"timeFrame":28},"Antimicrobial Redundancy Rate","Days of Therapy of prespecified redundant combinations of antimicrobials. Analysed at the ICU level.",{"measure":33,"description":34,"timeFrame":28},"Antimicrobial resistance rate","Number of multidrug-resistant pathogens (as specified by WHO priority list) \u002F number of patients",{"measure":36,"description":37,"timeFrame":28},"Antimicrobial prescribing rate","Number of patients receiving at least 1 antimicrobial \u002F number of patients admitted to ICU in the same period",null,{"allocation":38,"interventionModel":38,"interventionModelDescription":38,"primaryPurpose":38,"observationalModel":40,"timePerspective":41,"maskingInfo":38},"COHORT","PROSPECTIVE","All adult ICUs within CCAA-affiliated CQRs, where surveillance of antimicrobial utilisation has already been established will be considered for participation.\n\nICUs must appoint a named Champion in order to participate. A survey will be conducted to determine pre-existing prescribing practice and the presence, characteristics and current adoption of structured review activities. Pre-existing antimicrobial review processes are neither a requirement for an ICU to participate nor an exclusion criterion. Instead, parallel to the survey, pre-implementation patient-level data pertaining to current antimicrobial prescribing review practices will be measured during months 1-2. ICU's which are found to already have a structured antimicrobial review in place, and which demonstrate adoption and reach of 80% or greater (median over the 2 months) will not be eligible to participate in the implementation to reduce confounding of the selected measures for implementation success.",[44],{"type":45,"name":46,"description":47,"armGroupLabels":38,"otherNames":38},"BEHAVIORAL","Structured antimicrobial review","The appropriateness of the documented indication, route of administration, expected duration and stop date of all antimicrobials will be reviewed within 48 hours of their prescription.",[49],{"name":50,"affiliation":5,"role":51},"Abi Beane, Dr.","PRINCIPAL_INVESTIGATOR",[53,58],{"name":54,"role":55,"phone":56,"phoneExt":38,"email":57},"Duncan Wagstaff, PhD","CONTACT","0044(0)2076799060","d.wagstaff@ucl.ac.uk",{"name":59,"role":55,"phone":38,"phoneExt":38,"email":60},"Arjen Dondorp, Prof","arjen@tropmedres.ac",[62],{"facility":63,"status":64,"city":65,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"National Hospital for Tropical Diseases","RECRUITING","Hanoi","123000","Vietnam","VN",{"type":70,"coordinates":71},"Point",[72,73],105.84117,21.0245,{"lat":73,"lon":72},[76,78],{"name":77,"role":55,"phone":38,"phoneExt":38,"email":38},"Louise Thwaites",{"name":79,"role":55,"phone":38,"phoneExt":38,"email":38},"Yen Lam Minh",{"type":81,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[83],{"name":84,"class":85},"Nat Intensive Care Surveillence-MORU","UNKNOWN","100567326","evidence-based-quality-improvement-for-prescribing-stewardship-in-icu-equips-icu-100567326",false,"NCT06666738","Evidence Based QUality Improvement for Prescribing Stewardship in ICU (EQUIPS-ICU)","Evidence Based QUality Improvement for Prescribing Stewardship in ICU: Can a Structured Antimicrobial Review be Implemented in LMIC ICUs?","EQUIPS-ICU","Inclusion Criteria:\n\n* All adult ICUs within CCAA-affiliated Care Quality Registries\n* ICUs must appoint a named Champion to facilitate implementation\n* All antimicrobial prescriptions for adult patients within the ICUs described above\n\nExclusion Criteria:\n\n• ICU's which demonstrate adoption and reach of 80% or greater (median over 2 months) of a pre-existing structured antimicrobial review",true,"ALL","18 Years",{"count":98,"type":99},6300,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the implementation of a process to review antimicrobial prescriptions for adult patients in Intensive Care Unit (ICU).\n\nThe main question it aims to answer is: can a structured antimicrobial review can be implemented in ICUs?\n\nImplementation will be supported by the use of local protocols, audit and feedback, and education. It will be evaluated by daily data collection of clinical processes and interviews with local champions.\n\nResources to conduct the study are provided by the Wellcome Flagship Innovations award. (\"Collaboration for Research, Implementation and Training in Critical Care in Asia and Africa\", reference 224048\u002FZ\u002F21\u002FZ).",[103],"Antimicrobial Stewardship",[105,103,106,107,108],"Critical care","Implementation","Quality improvement","Low or Middle Income Country (LMIC)","2026-10-02",{"date":111,"type":112},"2026-10-07","ACTUAL",{"date":114,"type":112},"2025-01-13",{"date":116,"type":99},"2026-12-31",{"name":5,"class":6},1]